Symptoms and Quality of Life in Gastroenteropancreatic Neuroendocrine Tumours - European Medical Journal

Symptoms and Quality of Life in Gastroenteropancreatic Neuroendocrine Tumours

Download PDF
Sebastian Kaupp-Roberts,1 Rajaventhan Srirajaskanthan,2 *John K. Ramage1,2

No potential conflicts of interest.

EMJ Oncol. ;3[1]:34-40. DOI/10.33590/emjoncol/10313153.
Quality of life, patient-reported outcome measures (PROMs), gastroenteropancreatic neuroendocrine tumours (GEP-NETs), symptoms, GINET21, QLQ-C30, syndromes, neuroendocrine tumours (NETs).

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have the ability to induce symptoms either by their direct mass effect on local tissues (symptoms such as pain, bowel obstruction, obstructive  jaundice, and bleeding), or by the ectopic secretion of bioactive compounds. GEP-NETs are frequently associated with significant diagnostic delays, and metastatic disease is often a feature at initial  presentation. Quality of life (QoL) research in GEP-NETs is a comparatively new field, with a disease- specific QoL questionnaire, the QLQ-GINET21, having been fully validated only as recently as 2013. It has been reliably demonstrated to date that diarrhoea, fatigue, and flushing are the symptoms provoking  the greatest decline in patient QoL. Furthermore, depression is highly prevalent in the GEP-NET  population. This paper reviews current understanding and potential future developments in this field.

Please view the full content in the pdf above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally